chemieunternehmen.com

Evotec AG today announced that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/multi-target-alliance-with-bayer-5081

Evotec AG and Aspireo Pharmaceuticals Limited an Israeli biopharmaceutical company focused on the development of a novel somatostatin analogue, announced today that they have entered into a strategic advisory agreement for support in the development and partnering of Aspireo’s Somatoprim. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-aspireo-enter-into-strategic-advisory-agreement-5079

Evotec AG today announced that Evotec has entered into a multi-year compound management agreement with the National Institutes of Health, Department of Health and Human Services, for the operation of a Small Molecule Repository. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/nih-awards-major-contract-to-evotec-to-manage-and-operate-a-small-molecule-repository-5075

Evotec AG today reported financial results and corporate updates for the second quarter and first half of 2012 ending 30 June 2012. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/building-innovation-on-the-back-of-profitable-growth-5073

Evotec AG today announced that it has licensed to Janssen Pharmaceuticals, Inc. a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/curebeta-a-collaboration-between-evotec-and-harvard-university-enters-strategic-alliance-with-janssen-pharmaceuticals-5067

Evotec AG today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 4.0 million to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/milestone-payment-as-part-of-its-discovery-alliance-with-boehringer-ingelheim-received-5065

Evotec AG is proud to announce the addition of Agilent Technologies‘ RapidFire Mass Spectrometry analysis capabilities to their High Throughput Screening facilities in Hamburg. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-becomes-the-first-contract-research-facility-in-europe-to-offer-agilents-rapidfirems-screening-for-pharmaceutical-drug-discovery-5063

Evotec AG today reported financial results and corporate updates for the first quarter of 2012. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reports-continued-strong-revenue-growth-in-q1-2012-5061

Evotec AG and 4-Antibody AG today announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-and-4-antibody-ag-form-strategic-collaboration-to-innovate-antibody-selection-5059